Barinthus Biotherapeutics (NASDAQ:BRNS) Issues Quarterly Earnings Results, Beats Expectations By $0.13 EPS

Barinthus Biotherapeutics (NASDAQ:BRNS) issued its quarterly earnings data on Thursday. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.13, FiscalAI reports.

Barinthus Biotherapeutics Price Performance

Shares of BRNS stock traded up $0.01 on Thursday, hitting $0.65. 5,148 shares of the stock traded hands, compared to its average volume of 48,743. The company’s fifty day moving average is $0.67 and its 200 day moving average is $0.90. Barinthus Biotherapeutics has a 1-year low of $0.56 and a 1-year high of $2.92. The company has a market capitalization of $26.58 million, a PE ratio of -0.40 and a beta of -0.63.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Barinthus Biotherapeutics in a research note on Monday, December 22nd. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Barinthus Biotherapeutics presently has a consensus rating of “Hold” and a consensus price target of $4.00.

Institutional Trading of Barinthus Biotherapeutics

A hedge fund recently raised its stake in Barinthus Biotherapeutics stock. Renaissance Technologies LLC lifted its stake in shares of Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 115.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 143,100 shares of the company’s stock after purchasing an additional 76,800 shares during the quarter. Renaissance Technologies LLC owned about 0.35% of Barinthus Biotherapeutics worth $100,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 25.20% of the company’s stock.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.